advertisement

Topcon

Journal of Ocular Pharmacology and Therapeutics 8

Showing records 1 to 8 | Display all abstracts in Journal of Ocular Pharmacology and Therapeutics

9641 CNP-induced changes in pHi, cGMP/cAMP and mRNA expression of natriuretic peptide receptors in human trabecular meshwork cells
Zhong L; Chu E; Chu J; Chu TC
Journal of Ocular Pharmacology and Therapeutics 2003; 19: 425-436
9672 Real-time direct measurement of nitric oxide in bovine perfused eye trabecular meshwork using a Clark-type electrode
Millar JC
Journal of Ocular Pharmacology and Therapeutics 2003; 19: 299-313
9749 Laboratory assessment of diurnal and nocturnal ocular perfusion pressures in humans
Liu JHK; Gokhale PA; Loving RT; Kripke DF; Weinreb RN
Journal of Ocular Pharmacology and Therapeutics 2003; 19: 291-297
9906 A six-week, parallel, randomized, double-blind study comparing the efficacy and safety of the 0.5% timolol/2.0% MK-507 combination b.i.d. to the concomitant administration of 0.5% timolol b.i.d. and 2.0% MK-507 b.i.d.
Chen YF; Yang CH; Hung PT
Journal of Ocular Pharmacology and Therapeutics 2003; 19: 417-423
9919 Human ciliary muscle cell responses to FP-class prostaglandin analogues: phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation
Sharif NA; Crider JY; Husain S; Kaddour Djebbar I; Ansari HR; Abdel Latif AA
Journal of Ocular Pharmacology and Therapeutics 2003; 19: 437-455
9920 Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments
Zimmerman TJ; Stewart WC
Journal of Ocular Pharmacology and Therapeutics 2003; 19: 405-415
9934 Effects of brinzolamide on aqueous humor dynamics in monkeys and rabbits
Toris CB; Zhan GL; McLaughlin MA
Journal of Ocular Pharmacology and Therapeutics 2003; 19: 397-404
9949 AL-2512, a novel corticosteroid: preclinical assessment of anti-inflammatory and ocular hypertensive effects
Bhattacherjee P; Mukhopadhyay P; Paterson CA; Graff G; Gamache DA; Yanni JM
Journal of Ocular Pharmacology and Therapeutics 2003; 19: 353-360

Issue 5-3

Change Issue


advertisement

Oculus